S1314 correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation | Caris Life Sciences
Portal
Order
Home / Research / Publications / S1314 correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation

Publications

Back

S1314 correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation

– Caris Life Sciences

Poster

Background

We previously reported that MIBC harboring mutations in one or more of ATM , RB1 or FANCC is exquisitely responsive to platinum based NAC, resulting in a high rate of pathologic complete response (pT0) and excellent OS and DFS after surgery.

Download Publication

Discover
More

  • Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial

    – Caris Life Sciences

    Manuscript

    Abstract We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based… […]

  • A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

    – Caris Life Sciences

    Poster

    BACKGROUND Cisplatin-based neoadjuvant chemotherapy followed by cystectomy or chemoradiation is the standard of care for urothelial carcinoma patients with muscle invasive bladder cancer. Both cystectomy… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)